Abstract
MAPKAP-K2 (MK2) belongs to the Ser/Thr kinase family, and has emerged as a highly favored target in the search for efficacious and safe anti-inflammatory drug. Thus, 3D-QSAR and structure-based pharmacophore models were developed in this study to identify new potential leads inhibiting MK2 as an efficient way to treat rheumatoid arthritis. Furthermore, these two kinds of models were cascaded together to reduce false positives in virtual screening. The selected compounds were further analyzed and refined using drug-like filters and ADMET analysis. Subsequently, 105 recruited hits were docked into MK2-binding site with GOLD. Finally, 12 molecules were selected as potential MK2 inhibitors, and their consensus score and their structural diversity were evaluated.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Anderson DR, Hegde S, Reinhard E, Gomez L, Vernier WF, Lee L, Liu S, Sambandam A, Snider PA, Masih L (2005) Aminocyanopyridine inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2). Bioorg Med Chem Lett 15(6):1587–1590
Anderson DR, Meyers MJ, Vernier WF, Mahoney MW, Kurumbail RG, Caspers N, Gennadiy I, Schindler JF, Reitz DB, Mourey RJ (2007) Pyrrolopyridine inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2). J Med Chem 50(11):2647–2654
Anderson DR, Meyers MJ, Kurumbail RG, Caspers N, Poda GI, Long SA, Pierce BS, Mahoney MW, Mourey RJ, Parikh MD (2009) Benzothiophene inhibitors of MK2. Part 2: improvements in kinase selectivity and cell potency. Bioorg Med Chem Lett 19(16):4882–4884
Argiriadi MA, Ericsson AM, Harris CM, Banach DL, Borhani DW, Calderwood DJ, Demers MD, DiMauro J, Dixon RW, Hardman J, Kwak S, Li B, Mankovich JA, Marcotte D, Mullen KD, Ni B, Pietras M, Sadhukhan R, Sousa S, Tomlinson MJ, Wang L, Xiang T, Talanian RV (2010) 2,4-Diaminopyrimidine MK2 inhibitors. Part I: observation of an unexpected inhibitor binding mode. Bioorg Med Chem Lett 20(1):330–333
Barf T, Kaptein A, Wilde Sd, Heijden Rvd, Someren Rv, Demont D, Schultz-Fademrecht C, Versteegh J, Zeeland Mv, Seegers N, Kazemier B, Kar Bvd, Hoek Mv, Roos Jd, Klop H, Smeets R, Hofstra C, Hornberg J, Oubrie A (2011) Structure-based lead identification of ATP-competitive MK2 inhibitors. Bioorg Med Chem Lett 21(12):3818–3822
Clifton AD, Young PR, Cohen P (1996) A comparison of the substrate specificity of MAPKAP kinase-2 and MAPKAP kinase-3 and their activation by cytokines and cellular stress. FEBS Lett 392(3):209
Cohen P (2009) Targeting protein kinases for the development of anti-inflammatory drugs. Curr Opin Cell Biol 21(2):317–324
Fujino A, Fukushima K, Namiki N, Kosugi T, Takimoto-Kamimura M (2009) Structural analysis of an MK2-inhibitor complex: insight into the regulation of the secondary structure of the Gly-rich loop by TEI-I01800. Acta Crystallogr D 66(1):80–87
Gaestel M (2006) MAPKAP kinases-MKs-two’s company, three’s a crowd. Nat Rev Mol Cell Bio 7(2):120–130
Goldberg DR, Choi Y, Cogan D, Corson M, DeLeon R, Gao A, Gruenbaum L, Hao MH, Joseph D, Kashem MA, Miller C, Moss N, Netherton MR, Pargellis CP, Pelletier J, Sellati R, Skow D, Torcellini C, Tseng YC, Wang J, Wasti R, Werneburg B, Wu JP, Xiong Z (2008) Pyrazinoindolone inhibitors of MAPKAP-K2. Bioorg Med Chem Lett 18(3):938–941
Hammaker D, Firestein GS (2009) Go upstream, young man: lessons learned from the p38 saga. Ann Rheum Dis 69(Suppl 1):i77–i82
Harris CM, Ericsson AM, Argiriadi MA, Barberis C, Borhani DW, Burchat A, Calderwood DJ, Cunha GA, Dixon RW, Frank KE, Johnson EF, Kamens J, Kwak S, Li B, Mullen KD, Perron DC, Wang L, Wishart N, Wu X, Zhang X, Zmetra TR, Talanian RV (2010) 2,4-Diaminopyrimidine MK2 inhibitors. Part II: structure-based inhibitor optimization. Bioorg Med Chem Lett 20(1):334–337
Huang N, Shoichet BK, Irwin JJ (2006) Benchmarking sets for molecular docking. J Med Chem 49(23):6789–6801
Hutchinson E, Michie A, Wallace A, Jones M, Thornton J (1997) PDBsum: a web-based database of summaries and analyses of all PDB structures. Trends Biochem Sci 22(12):488–490
Jones G, Willett P, Glen RC, Leach AR, Taylor R (1997) Development and validation of a genetic algorithm for flexible docking. J Mol Bio 267(3):727–748
Kaptein A, Oubrie A, Zwart Ed, Hoogenboom N, Jd Wit, Bvd Kar, Mv Hoek, Vogel G, Vd Kimpe, Schultz-Fademrecht C, Borsboom J, Mv Zeeland, Versteegh J, Kazemier B, Jd Roos, Wijnands F, Dulos J, Jaeger M, Leandro-Garcia P, Barf T (2011) Discovery of selective and orally available spiro-3-piperidyl ATP-competitive MK2 inhibitors. Bioorg Med Chem Lett 21(12):3823–3827
Leeson PD, Springthorpe B (2007) The influence of drug-like concepts on decision-making in medicinal chemistry. Nat Rev Drug Discov 6(11):881–890
Lin S, Lombardo M, Malkani S, Hale JJ, Mills SG, Chapman K, Thompson JE, Zhang WX, Wang R, Cubbon RM, O’Neill EA, Luell S, Carballo-Jane E, Yang L (2009) Novel 1-(2-aminopyrazin-3-yl)methyl-2-thioureas as potent inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2). Bioorg Med Chem Lett 19(12):3238–3242
Lipinski CA (2004) Lead- and drug-like compounds: the rule-of-five revolution. Drug Discov Today Technol 1(4):337–341
Lovering F, Kirincich S, Wang W, Combs K, Resnick L, Sabalski JE, Butera J, Liu J, Parris K, Telliez J (2009) Identification and SAR of squarate inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2). Bioorg Med Chem 17(9):3342–3351
Olsson H, Sjö P, Ersoy O, Kristoffersson A, Larsson J, Nordén B (2010) 4-Anilino-6-phenyl-quinoline inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK2). Bioorg Med Chem Lett 20(16):4738–4740
Revesz L, Schlapbach A, Aichholz R, Feifel R, Hawtin S, Heng R, Hiestand P, Jahnke W, Koch G, Kroemer M, Möbitz H, Scheufler C, Velcicky J, Huppertz C (2010a) In vivo and in vitro SAR of tetracyclic MAPKAP-K2 (MK2) inhibitors. Part I. Bioorg Med Chem Lett 20(15):4715–4718
Revesz L, Schlapbach A, Aichholz R, Dawson J, Feifel R, Hawtin S, Littlewood-Evans A, Koch G, Kroemer M, Möbitz H, Scheufler C, Velcicky J, Huppertz C (2010b) In vivo and in vitro SAR of tetracyclic MAPKAP-K2 (MK2) inhibitors. Part II. Bioorg Med Chem Lett 20(15):4719–4723
Ronkina N, Menon MB, Schwermann J, Tiedje C, Hitti E, Kotlyarov A, Gaestel M (2010) MAPKAP kinases MK2 and MK3 in inflammation: complex regulation of TNF biosynthesis via expression and phosphorylation of tristetraprolin. Biochem Pharmacol 80(12):1915–1920
Schlapbach A, Feifel R, Hawtin S, Heng R, Koch G, Moebitz H, Revesz L, Scheufler C, Velcicky J, Waelchli R, Huppertz C (2008) Pyrrolo-pyrimidones: a novel class of MK2 inhibitors with potent cellular activity. Bioorg Med Chem Lett 18(23):6142–6146
Stokoe D, Caudwell B, Cohen P, Cohen P (1993) The substrate specificity and structure of mitogen-activated protein (MAP) kinase-activated protein kinase-2. Biochem J 296(3):843
Thangapandian S, John S, Sakkiah S, Lee KW (2010) Ligand and structure based pharmacophore modeling to facilitate novel histone deacetylase 8 inhibitor design. Eur J Med Chem 45(10):4409–4417
Thangapandian S, John S, Sakkiah S, Lee KW (2011) Potential virtual lead identification in the discovery of renin inhibitors: application of ligand and structure-based pharmacophore modeling approaches. Eur J Med Chem 46(6):2469–2476
Underwood K, Parris K, Federico E, Mosyak L, Czerwinski R, Shane T, Taylor M, Svenson K, Liu Y, Hsiao C (2003) Catalytically active MAP KAP kinase 2 structures in complex with staurosporine and ADP reveal differences with the autoinhibited enzyme. Structure 11(6):627–636
Van de Waterbeemd H, Gifford E (2003) ADMET in silico modelling: towards prediction paradise? Nat Rev Drug Discov 2(3):192–204
Velcicky J, Feifel R, Hawtin S, Heng R, Huppertz C, Koch G, Kroemer M, Moebitz H, Revesz L, Scheufler C, Schlapbach A (2010) Novel 3-aminopyrazole inhibitors of MK-2 discovered by scaffold hopping strategy. Bioorg Med Chem Lett 20(3):1293–1297
Wallace AC, Laskowski RA, Thornton JM (1995) LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng 8(2):127–134
Wang Y, Bolton E, Dracheva S, Karapetyan K, Shoemaker BA, Suzek TO, Wang J, Xiao J, Zhang J, Bryant SH (2010) An overview of the PubChem BioAssay resource. Nucleic Acids Res 38 (Database):D255–D266
Wu J-P, Wang J, Abeywardane A, Andersen D, Emmanuel M, Gautschi E, Goldberg DR, Kashem MA, Lukas S, Mao W, Martin L, Morwick T, Moss N, Pargellis C, Patel UR, Patnaude L, Peet GW, Skow D, Snow RJ, Ward Y, Werneburg B, White A (2007) The discovery of carboline analogs as potent MAPKAP-K2 inhibitors. Bioorg Med Chemy Lett 17(16):4664–4669
Xiong Z, Gao DA, Cogan DA, Goldberg DR, Hao M-H, Moss N, Pack E, Pargellis C, Skow D, Trieselmann T, Werneburg B, White A (2008) Synthesis and SAR studies of indole-based MK2 inhibitors. Bioorg Med Chem Lett 18(6):1994–1999
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Wang, TJ., Zhou, L., Fei, J. et al. Applications of 3D-QSAR and structure-based pharmacophore modeling, virtual screening, ADMET, and molecular docking of putative MAPKAP-K2 (MK2) inhibitors. Med Chem Res 22, 4818–4829 (2013). https://doi.org/10.1007/s00044-013-0492-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00044-013-0492-9